Experimental analyses of RFdiffusion designed Miniproteins for binding to SARS-CoV-2 nucleocapsid protein.

Miniprotein designs are emerging as promising antibody alternatives for therapeutic and diagnostic use. Using RFdiffusion, we designed 538 binder candidates targeting both N and C-terminal domains of the SARS-CoV-2 nucleocapsid protein, selecting 19 for recombinant production in E. coli. All were soluble and purified (8-10 mg/L yield), though 13 unexpectedly formed oligomers. CD spectroscopy confirmed proper folding and thermal refolding, with 9 miniproteins exhibiting Tm > 75°C. Binding assay revealed three miniproteins with affinities of 115 nM, 4.8 μM, and 7.32 μM. The 1.8 Å resolution crystal structure of one binder (Gpx62) matched the predicted design. However, predictive metrics (like ipTM of AlphaFold3 and computational simulations) did not align with experimental data. Together, these results reveal unintended oligomerization as a major, previously underappreciated barrier in miniprotein binder discovery, demonstrating that while RFdiffusion reliably predicts structural integrity and stability of miniprotein, its current metrics do not account for the oligomeric behavior that might critically limit binding competence.